Abstract: SA-PO0431
Random Plasma GLP-1 and Diabetic Kidney Disease in Adults with Type 2 Diabetes: A Multicenter Iraqi Case-Control Study
Session Information
- CKM: Clinical - Epidemiology and Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Authors
- Al-Saegh, Riyadh Muhi A., University of Kerbala, Karbala, Iraq
- Al-Tu'ma, Fadhil Jawad, University of Kerbala, Karbala, Karbala Governorate, Iraq
- Alajeeli, Muhammed Ibrahim hamad, University of Kerbala, Karbala, Karbala Governorate, Iraq
- Al-Saegh, Ameer Riyadh, Kerbala Health Directorate, Karbala, Iraq
Group or Team Name
- Al Saegh research group
Background
Diabetic kidney disease (DKD) complicates type 2 diabetes. GLP-1 has metabolic and renal effects, but levels vary with assay, meals, sample handling, kidney function, and drugs.
Methods
This case-control study included 171 participants: 51 with type 2 diabetes and DKD, 60 with diabetes without DKD, and 60 healthy controls. DKD was defined by KDIGO eGFR and albuminuria criteria. Random nonfasting plasma total GLP-1 was measured by ELISA. Associations were tested using Spearman correlation. Adjusted logistic regression and ROC analysis assessed DKD association and discrimination.
Results
Median total GLP-1 was highest in DKD, intermediate in diabetes without DKD, and lowest in controls: 88.0 (49.0–92.0), 52.0 (25.3–88.0), and 35.6 (28.3–41.6) pmol/L (P<0.001). It correlated with creatinine (r=0.361), CKD stage (r=0.335), albuminuria (r=0.285), and inversely with eGFR (r=−0.321). It was not independently associated with DKD (OR 1.009; P=0.574). ROC AUC was 0.683.
Conclusion
Total Plasma GLP-1 higher in DKD with modest diagnostic and association value.
Acknowledgment
The authors thank Alsaegh Nephrology Center, hospitals, and laboratory teams for their support.
Participant characteristics and key total GLP-1 findings
| Measure | DKD (n=51) | Diabetes without DKD (n=60) | Control (n=60) | P value / statistic |
| Age, years | 56.8 ± 12.4 | 53.4 ± 11.6 | 52.4 ± 13.8 | 0.110 |
| BMI,kg/m2 | 26.9 ± 4.49 | 28.1 ± 3.22 | 26.7 ± 3.59 | 0.221 |
| Male sex, n (%) | 29 (57) | 28 (47) | 30 (50) | 0.556 |
| Total GLP-1, pmol/L | 88.0 (49.0–92.0) | 52.0 (25.3–88.0) | 35.6 (28.3–41.6) | <0.001 |
| Adjusted GLP-1 association with DKD | - | - | - | OR 1.009 (95% CI 0.978–1.040); P=0.574 |
Values are mean±SD, n (%), or median (IQR). GLP-1 was random plasma total GLP-1. Models included diabetics. ROC assessed DKD vs diabetes. DKD,diabetic kidney disease; GLP-1, glucagon-like peptide-1;
Funding
- Private Foundation Support